MindRank’s MRANK-103 Achieves PCC Nomination and Advances into IND-Enabling Studies for MYC-Driven Cancers
MindRank
AI Drug Developer
On July 29, MindRank, which focuses on using AI-driven new drug development, announced that its molecular glue project designed for the MYC signaling pathway target—regulator of eukaryotic translation and transcription—successfully nominated a preclinical candidate compound (PCC) with its self-developed new drug MRANK-103, advancing into the IND-Enabling stage. This isThe fifth PCC molecule nominated by MindRank.
The ProjectUtilizeMindRankThe self-developed AI-driven molecular glue rational design platform ProtaG™ has identified candidate molecules for cancers that currently lack effective treatments or have suboptimal therapeutic drugs, such as CDK4/6 breast cancer resistance, colorectal cancer, lung cancer, and gastric cancer.
Preclinical studies have shown,MRANK-103It has a strong degradation ability for the target, with a degradation efficiency close to 100% and a DC50 at the picomolar activity level. Cell models show,MRANK-103Significant efficacy and ultra-high brain permeability; expected to be used for the treatment of lung cancer, breast cancer, and their brain metastases.MRANK-103It demonstrated potent anti-tumor cell proliferation activity in multiple models, including breast cancer, non-small cell lung cancer, and small cell lung cancer (especially for MYC-High tumors), with favorable pharmacokinetics and safety.
About ProtaG™ Platform
ProtaG™ is an AI-powered rational design platform for the rapid development of a new generation of molecular glue drugs targeting previously "undruggable" disease-causing protein targets. The platform integrates comprehensive molecular glue/Protac biological and chemical information data, which has been refined through large models combined with manual verification. Empowered by high-quality data, it accelerates the development of molecular glue pipelines under target and E3 ligase-driven strategies via artificial intelligence combined with molecular dynamics simulations.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.
The AI pharmaceutical solution of the company was rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list.
Source: MindRank
